Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy classification of modern therapies in multiple sclerosis.
Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Häring DA, Stoneman D, Klotz L, Adlard N. Samjoo IA, et al. Among authors: worthington e. J Comp Eff Res. 2021 Apr;10(6):495-507. doi: 10.2217/cer-2020-0267. Epub 2021 Feb 23. J Comp Eff Res. 2021. PMID: 33620251 Free article.
The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
Samjoo IA, Worthington E, Haltner A, Cameron C, Nicholas R, Dahlke F, Adlard N. Samjoo IA, et al. Among authors: worthington e. Curr Med Res Opin. 2020 Jul;36(7):1145-1156. doi: 10.1080/03007995.2020.1747998. Epub 2020 Apr 14. Curr Med Res Opin. 2020. PMID: 32216597
Letter in reply.
Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Häring DA, Stoneman D, Klotz L, Adlard N. Samjoo IA, et al. Among authors: worthington e. J Comp Eff Res. 2021 Dec;10(17):1267-1269. doi: 10.2217/cer-2021-0203. Epub 2021 Oct 5. J Comp Eff Res. 2021. PMID: 34608814 Free article. No abstract available.
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo IA, Klotz L, Giovannoni G, Drudge C, Haltner A, Worthington E, Zhao M, Brennan R, Häring DA, Cameron C, Adlard N. Samjoo IA, et al. Among authors: worthington e. Mult Scler Relat Disord. 2022 Oct;66:104031. doi: 10.1016/j.msard.2022.104031. Epub 2022 Jul 4. Mult Scler Relat Disord. 2022. PMID: 35841716
153 results